Advances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), 2nd Edition
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 68
Special Issue Editor
Interests: gut-brain axis; neuroimmune disease; GI-associated plasmacytoid dendritic cells; Alzheimer’s disease; myalgic encephalomyelitis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is a continuation of our previous Special Issue, “Advances of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)”.
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is an illness of unknown etiology, characterized by multiple physical symptoms and comorbid conditions. Symptoms often reported by those with ME/CFS include unexplained fatigue that lasts for more than six months, post-exertional malaise, neurocognitive problems, unrefreshing sleep, and gastrointestinal issues. Clinical laboratory findings often include inflammatory sequelae, metabolic disturbances, self-reactive antibodies, and immune cell abnormalities. Although many who suffer from ME/CFS report that they developed the condition following a “flu-like” illness from which they never fully recovered, an etiological agent has not been reproducibly identified. Likewise, many individuals infected by the SARS-CoV-2 virus often never fully recover and present with symptoms that significantly overlap with those of ME/CFS. This syndrome is typically referred to as long COVID-19 or post-acute sequelae of SARS COV-2 infection. In this Special Issue, which addresses the advances in research regarding myalgic encephalomyelitis/chronic fatigue syndrome, we aim to publish original research papers and reviews that focus on the involvement of the immune system in ME/CFS. Reports that leverage commonalities between ME/CFS and long COVID-19 to identify the mechanisms behind immune abnormalities are highly encouraged.
Dr. Vincent C. Lombardi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ME/CFS
- PASC
- long COVID-19
- inflammation
- innate immunity
- adaptive immunity
- mast cell activation
- post-infection syndrome
- metabolism
- autoantibodies
